In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.
Topics of conversation include the following:
- An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
- Targeting HER2 in lung cancer: where does IHC testing fit in?
- Ovarian cancer: challenges and considerations for HER2 IHC testing
- A panel discussion amongst speakers and participants engaging in a Q&A to address pressing issues
Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.
Clinical takeaways
- Standardise HER2 IHC for lung and ovarian carcinoma patients to ensure consistent and reliable results
- Implement high-quality HER2 IHC testing by:
- Engaging in pre-analytical processes
- Using validated IHC assays
- Adopting scoring and reporting guidelines (e.g., 3+ with a 10% cut-off)
- Implement high-quality HER2 IHC testing by:
- HER2 alterations in lung carcinoma encompass both amplifications and mutations, highlighting the importance of comprehensive testing for accurate diagnosis and treatment planning
- Incorporate HER2 testing earlier in the patient journey for ovarian carcinoma to guide timely and informed treatment decisions
- Emerging HER2-targeted therapies with antibody-drug conjugates are showing promise in the treatment of HER2-altered ovarian and lung cancers